Shanghai Chest Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1957-01-01

Employees: -

Market Cap: -

Website: http://www.shmtppp.com/hospitals/chest

Clinical Trials

171

Active:7

Completed:19

Trial Phases

5 Phases

Phase 1:10

Phase 2:41

Phase 3:9

+2 more phases

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (134 trials with phase data)• Click on a phase to view related trials

Not Applicable

70 (52.2%)

Phase 2

41 (30.6%)

Phase 1

10 (7.5%)

Phase 3

9 (6.7%)

Phase 4

4 (3.0%)

Clinical Validation Study on the Imaging Efficacy of Mobile 4D CBCT Technology for Peripheral Pulmonary Lesions

Not yet recruiting

Conditions: Peripheral Pulmonary Lesions (PPLs)

First Posted Date: 2025-09-02

Last Posted Date: 2025-09-08

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 50

Registration Number: NCT07149597

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, China

Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC

Not yet recruiting

Conditions: Lung Cancer
Neoadjuvant Therapy

First Posted Date: 2025-08-22

Last Posted Date: 2025-08-22

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 400

Registration Number: NCT07135856

Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules

Not Applicable

Not yet recruiting

Conditions: Lung Cancer (Diagnosis)

First Posted Date: 2025-08-22

Last Posted Date: 2025-08-22

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 465

Registration Number: NCT07135297

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳
Henan Provincial People's Hospital, Zhengzhou, Henan, China
🇨🇳
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China

and more 2 locations

Optimized Ablation of the Posterior Wall in Persistent Atrial Fibrillation

Not Applicable

Recruiting

Conditions: Persistent Atrial Fibrillation

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 384

Registration Number: NCT07122336

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, China

A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Not Applicable

Active, not recruiting

Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Chemoradiotherapy
Induction Therapy
Consolidation Immunotherapy

Interventions: Drug: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

First Posted Date: 2025-07-29

Last Posted Date: 2025-07-29

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 28

Registration Number: NCT07091305

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, China

News

Everest Medicines Advances AI-Powered mRNA Platform with Cancer Vaccine Breakthroughs

2 months ago

Everest Medicines unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day, showcasing a fully integrated system spanning antigen design to manufacturing.

Chinese Drug Combination Outperforms Keytruda in Advanced Lung Cancer Trial

3 months ago

A Chinese-developed drug combination of Benmelstobart and Anlotinib demonstrated superior efficacy over pembrolizumab (Keytruda) in treating PD-L1-positive advanced non-small cell lung cancer patients.